Liver toxicity induced by combined external-beam irradiation and radioimmunoglobulin therapy

Journal Article · Wed Mar 01 04:00:00 EST 1995 · Radiation Research

DOI:https://doi.org/10.2307/3579006· OSTI ID:81196

Wang, S; Quadri, S M; Tang, X Z; Vriesendorp, H M; Stephens, L C ^[1]; Lollo, C P; Bartholomew, R M ^[2]

---

1. Univ. of Texas M.D. Anderson Cancer Center, Houston, TX (United States)
2. Hybritech Inc., San Diego, CA (United States)

High-dose radiation therapy for liver metastases of gastrointestinal malignancies might be improved by combining external-beam irradiation and radioimmunoglobulin therapy. We studied the liver toxicity of the proposed combination in healthy beagle dogs. A total dose of 30 Gy to the whole liver, delivered in 2-Gy fractions over 3 weeks, resulted in mild, temporary veno-occlusive disease (VOD) in three of three dogs. Reversible bone marrow damage was noted after two intravenous injections of 18.5 MBq of yttrium-90-labeled monoclonal antibody ZCE025 per kg body weight in three of three dogs. Administrations of the antibody were separated by 1 week. Three dogs treated by irradiation of the liver with radioimmunoglobulin therapy added during the last 2 weeks of the irradiation showed signs of radiation hepatitis (VOD) starting around 35 days after treatment. One dog had a complete recovery, and two dogs were euthanized in a stage of terminal liver failure around day 90 after treatment. Temporary bone marrow damage was observed after the combined treatment, similar to the bone marrow damage observed after radioimmunoglobulin therapy alone. Earlier studies in the same dog model showed that bone marrow is the dose-limiting organ if radioimmunoglobulin therapy is used alone. The addition of irradiation of the liver to radioimmunoglobulin therapy changes the dose-limiting organ from bone marrow to liver. The radiation hepatitis observed in dogs is very similar to that observed in humans and is reflected in early platelet consumption in the irradiated liver plus late elevations of liver enzymes and VOD in central hepatic veins on histological analysis. Future applications of combined liver irradiation and radioimmunoglobulin therapy in humans should use radioimmunoglobulin therapy agents which show minimal uptake by normal liver. 20 refs., 7 figs., 4 tabs.

• Sponsoring Organization: USDOE
• OSTI ID: 81196
• Journal Information: Radiation Research, Journal Name: Radiation Research Journal Issue: 3 Vol. 141; ISSN RAREAE; ISSN 0033-7587
• Country of Publication: United States
• Language: English

Related Subjects

55 BIOLOGY AND MEDICINE
BASIC STUDIES
BIOLOGICAL RADIATION EFFECTS
BONE MARROW
COMBINED THERAPY
DOGS
FEASIBILITY STUDIES
HEPATITIS
LIVER
METASTASES
MONOCLONAL ANTIBODIES
RADIOIMMUNOTHERAPY
RADIOTHERAPY
YTTRIUM 90